Literature DB >> 9652995

Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial.

S Grinspoon1, C Corcoran, H Askari, D Schoenfeld, L Wolf, B Burrows, M Walsh, D Hayden, K Parlman, E Anderson, N Basgoz, A Klibanski.   

Abstract

BACKGROUND: Development of successful anabolic strategies to reverse the loss of lean body mass is of critical importance to increase survival in men with the AIDS wasting syndrome. Hypogonadism, an acquired endocrine deficiency state characterized by loss of testosterone, occurs in more than half of all men with advanced HIV disease. It is unknown whether testosterone deficiency contributes to the profound catabolic state and loss of lean body mass associated with the AIDS wasting syndrome.
OBJECTIVE: To investigate the effects of physiologic testosterone administration on body composition, exercise functional capacity, and quality of life in androgen-deficient men with the AIDS wasting syndrome.
DESIGN: Randomized, double-blind, placebo-controlled study.
SETTING: University medical center. PATIENTS: 51 HIV-positive men (age 42 +/- 8 years) with wasting (body weight < 90% of ideal body weight or weight loss > 10% of baseline weight) and a free testosterone level less than 42 pmol/L (normal range for men 18 to 49 years of age, 42 to 121 pmol/L [12.0 to 35.0 pg/mL]). INTERVENTION: Patients were randomly assigned to receive testosterone enanthate, 300 mg, or placebo intramuscularly every 3 weeks for 6 months. MEASUREMENTS: Change in fat-free mass was the primary end point. Secondary clinical end points were weight, lean body mass, muscle mass, exercise functional capacity, and change in perceived quality of life. Virologic variables were assessed by CD4 count and viral load.
RESULTS: Compared with patients who received placebo, testosterone-treated patients gained fat-free mass (-0.6 kg and 2.0 kg; P = 0.036), lean body mass (0.0 kg and 1.9 kg; P = 0.041), and muscle mass (-0.8 kg and 2.4 kg; P = 0.005). The changes in weight, fat mass, total-body water content, and exercise functional capacity did not significantly differ between the groups. Patients who received testosterone reported benefit from the treatment (P = 0.036), feeling better (P = 0.033), improved quality of life (P = 0.040), and improved appearance (P = 0.021). Testosterone was well tolerated in all patients.
CONCLUSIONS: Physiologic testosterone administration increases lean body mass and improves quality of life among androgen-deficient men with the AIDS wasting syndrome.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652995     DOI: 10.7326/0003-4819-129-1-199807010-00005

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  18 in total

1.  Metabolic Complications of HIV and AIDS.

Authors:  Alison Strawford; Marc K. Hellerstein
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

2.  HIV and aerobic exercise. Current recommendations.

Authors:  W W Stringer
Journal:  Sports Med       Date:  1999-12       Impact factor: 11.136

Review 3.  Regulation of body composition by androgens.

Authors:  S Bhasin
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

4.  Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels.

Authors:  S Bhasin; T W Storer; M Javanbakht; N Berman; K E Yarasheski; J Phillips; M Dike; I Sinha-Hikim; R Shen; R D Hays; G Beall
Journal:  JAMA       Date:  2000-02-09       Impact factor: 56.272

5.  Effects of Testosterone Supplementation on Body Composition in HIV Patients: A Meta-analysis of Double-blinded Randomized Controlled Trials.

Authors:  Ting Zhou; Zhi-Yong Hu; Hui-Ping Zhang; Kai Zhao; Yu Zhang; Ying Li; Jia-Jing Wei; Hong-Fang Yuan
Journal:  Curr Med Sci       Date:  2018-03-15

6.  Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial): design and methods.

Authors:  Nathan K LeBrasseur; Newsha Lajevardi; Renee Miciek; Norman Mazer; Thomas W Storer; Shalender Bhasin
Journal:  Contemp Clin Trials       Date:  2008-10-29       Impact factor: 2.226

Review 7.  Hypogonadism in human immunodeficiency virus-positive men.

Authors:  Jane Ashby; David Goldmeier; Hossein Sadeghi-Nejad
Journal:  Korean J Urol       Date:  2014-01-15

Review 8.  A practical guide to male hypogonadism in the primary care setting.

Authors:  P Dandona; M T Rosenberg
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

9.  Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial.

Authors:  Sara E Dolan Looby; Merredith Collins; Hang Lee; Steven Grinspoon
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

10.  Oxandrolone does not improve outcome of ventilator dependent surgical patients.

Authors:  Eileen M Bulger; Gregory J Jurkovich; Catherine L Farver; Patricia Klotz; Ronald V Maier
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.